EWA
PRME icon

EverSource Wealth Advisors’s Prime Medicine PRME Stock Holding History

EverSource Wealth Advisors’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.96K Buy
2,000
+238
+14% +$906 ﹤0.01% 3104
2025
Q4 		$6.11K Hold
1,762
– – ﹤0.01% 3039
2025
Q3 		$9.76K Buy
1,762
+400
+29% +$1.63K ﹤0.01% 2834
2025
Q2 		$3.36K Buy
1,362
+350
+35% +$540 ﹤0.01% 3313
2025
Q1 		$2.01K Buy
1,012
+1,006
+16,767% +$2.57K ﹤0.01% 2929
2024
Q4 		$18 Sell
6
-100
-94% -$351 ﹤0.01% 3715
2024
Q3 		$410 Hold
106
– – ﹤0.01% 2905
2024
Q2 		$595 Buy
+106
New +$643 ﹤0.01% 2852

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

EverSource Wealth Advisors's PRME Position: Q1 2026 in Review

EverSource Wealth Advisors increased its Prime Medicine (PRME) stake by 14% in Q1 2026, buying an estimated $906 and bringing the position to 2,000 shares worth $6.96K. The position accounts for ﹤0.01% of the portfolio, ranked #3104.

EverSource Wealth Advisors first reported a position in PRME in Q2 2024 and has held it in 8 quarters since. The position peaked at $9.76K in Q3 2025. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • EverSource Wealth Advisors held 2,000 shares of Prime Medicine worth $6.96K as of Q1 2026.
  • EverSource Wealth Advisors bought 238 Prime Medicine shares in Q1 2026, an estimated $906.
  • Prime Medicine made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q1 2026, its #3104 holding.
  • EverSource Wealth Advisors first reported a position in Prime Medicine in Q2 2024 and has held it in 8 quarters since.
  • EverSource Wealth Advisors's Prime Medicine position peaked at $9.76K in Q3 2025.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.